Whether Epclusa can cure hepatitis C 100% and its realistic assessment

Epclusa is a fully oral anti-hepatitis C virus (HCV) pan-genotype treatment regimen composed of sofosbuvir and velpatasvir. Because it covers the six major genotypes of HCV and the treatment course only takes 12 weeks, it has extremely high curative potential in clinical applications. According to a number of international large-scale clinical trials, the sustained virological response rate (SVR12, that is, no virus is detected 12 weeks after the end of treatment) of Jisandai can reach 95% or more, and even close to 100% in some people. However, this high cure rate of "close to 100%" may still be affected by many factors in real clinical practice.

Individual differences among patients will affect the efficacy of Jisandai. Although Jisandai has shown excellent efficacy in most hepatitis C patients, in some patients with severe cirrhosis, extremely impaired liver function, or other comorbidities (such as HIV co-infection), the cure rate may be slightly lower than that of the general population. In addition, if patients who have failed to use antiviral drugs in the past have resistance-related mutations, they may also affect the final efficacy. Therefore, clinicians usually conduct a comprehensive evaluation based on medical history before prescribing drugs.

Compliance is an important factor in determining efficacy. Jisandai is an all-oral therapy and is relatively simple to take. However, if the patient misses a dose, stops taking the drug, or shortens the course of treatment on his own, it may lead to failure of virus clearance and even drug resistance. Therefore, strictly following the doctor's instructions to complete the 12 weeks or even 24 weeks of treatment (for some special groups) is the key to ensuring a high cure rate. Doctors will also regularly monitor viral load and liver function to ensure the effectiveness of the treatment.

It needs to be emphasized that although the clinical cure rate of Jisandai is very high, it is currently not guaranteed to be "100%". In reality, a small number of patients may not be able to completely eliminate the virus due to drug resistance, drug interactions, or severe liver damage. However, from the perspective of long-term clinical experience, Jisandai has been regarded as a milestone drug in the field of hepatitis C treatment. Its high efficiency, safety and short treatment course have greatly promoted the realization of the goal of "curable" hepatitis C. For the vast majority of patients, Jisandai is undoubtedly one of the most effective and practical treatment options at present.

Reference materials:https://www.drugs.com/